Trial Profile
A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY OF 18F-SODIUM FLUORIDE PET/CT BONE IMAGING IN ENZALUTAMIDE-TREATED CHEMOTHERAPY-NAÏVE PATIENTS WITH BONE-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors Medivation; Pfizer
- 08 Sep 2020 Results published in the Journal of Clinical Oncology
- 04 Jun 2019 Primary endpoint has been met. (Proportion of patients with at least one responding bone lesion (defined as a lesion with a total standardized uptake value less than that at baseline) on the third 18F-NaF PET/CT scan performed for each patient)
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology